FindTrial
Sign In

Safety of Latanoprost Eyedrops

Safety and Stabilty of Topical Latanoprost Eye Drops: A Randomised Prospective Observational Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037348
Enrollment
80
Registered
2021-10-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H409- Unspecified glaucoma

Interventions

Control Intervention1: Observational study: We are including patients already on Latanoprost. Its just an observational study

Sponsors

Aravind Eye Hospital Pondicherry
Lead Sponsor
Aurolab
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients using Latanoprost eyedrops

Exclusion criteria

Exclusion criteria: Patients using glaucoma eyedrops other than Latanoprost

Design outcomes

Primary

MeasureTime frame
To assess the concentration of the eyedrops at the end of 4 and 6 weeks after opening the eye bottle as compared to the baselineTimepoint: 4 and 6 weeks—

Secondary

MeasureTime frame
To assess the contamination levels at 4 and 6 weeksTimepoint: 4 and 6 weeks—

Countries

India

Contacts

Public ContactDr Vishwaraj C R

Aravind Eye Hospital

vishwarajcr@gmail.com09972856386

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026